Background and objective: Cluster analysis has been utilized to explore phenotypic heterogeneity in chronic obstructive pulmonary disease (COPD). To date, little is known about the longitudinal variability of clusters in COPD patients. We aimed to evaluate the 2-year cluster variability in stable COPD patients. Methods: We evaluated the following variables in COPD patients at baseline and 2 years later: age, gender, packyear history, body mass index (BMI), modified Medical Research Council (MMRC) scale, 6-min walking distance (6MWD), spirometry and COPD Assessment Test (CAT). Patient classification was performed using cluster analysis at baseline and 2 years later. Each patient's cluster variability after 2 years and its parameters associated with cluster change were explored. Results: A total of 521 smokers with COPD were evaluated at baseline and 2 years later. Three different clusters were consistently identified at both evaluation times: cluster A (of younger age, mild airway limitation, few symptoms), cluster B (intermediate) and cluster C (of older age, severe airway limitation and highly symptomatic). Two years later, 70% of patients were unchanged, whereas 30% changed from one cluster to another: 20% from A to B; 15% from B to A; 15% from B to C; 42% from C to B and 8% from C to A. 6MWD, forced expiratory volume in 1 s (FEV 1 ) % and CAT were the principal parameters responsible for this change. Conclusion: After 2 years of follow-up, most of the COPD patients maintained their cluster assignment. Exercise tolerance, lung function and quality of life were the main driving parameters in those who change their cluster assignment.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is an important health problem and is ranked as the third disease burden worldwide since 2010. 1 COPD is characterized by a persistent airflow limitation that is usually progressive and is associated with an enhanced chronic inflammatory response in the airways and lungs to noxious particles or gases, primarily cigarette smoke. 2 COPD is a complex disease with a heterogeneous clinical presentation. 3 Several efforts have been conducted to classify COPD patients into subgroups or clinical phenotypes to allow their easy identification regarding prognostic and therapeutic purposes. [4] [5] [6] [7] [8] [9] Cluster analysis, whose aim is to organize information so that heterogeneous groups of variables can be classified into relatively homogeneous groups, 10 has been proposed for the examination of clinical phenotypic heterogeneity in COPD patients. Several studies have investigated different databases, identifying
SUMMARY AT A GLANCE
This longitudinal analysis of a large chronic obstructive pulmonary disease (COPD) study explored the identification of clusters and their behaviour over 2 years. We validated previous data on the topic but in a multicentre study and with 2 years of follow-up (previously only 1 year). We also identified factors associated with cluster changes. different clusters, but to date, most of them were in cross-sectional studies. [4] [5] [6] [7] [8] [9] Recent data suggest that the most important clinical characteristics of COPD patients could change longitudinally 11 and probably each patient cluster assignment could also change over time. A recent study from Spain reported data on cluster variability in stable COPD patients, 12 suggesting that COPD clusters remain stable over 1 year. To validate these findings, we postulated that clusters of COPD patients are not only stable longitudinally for 1 year but also for 2 years. We therefore explored the identification of clusters at baseline and 2 years after, cluster changes during this time and the parameters associated with these changes.
METHODS

Participants
COPD History Assessment In SpaiN (CHAIN) is a Spanish multicentre study carried out at respiratory medicine clinics. Both active and former smokers with COPD were included. The methodological aspects of the study have been previously described. 13 The definition of the disease was established by a history of smoking of at least 10 pack-years and postbronchodilator forced expiratory volume in 1 s/forced vital capacity (FEV 1 /FVC) ratio <0.70 after the inhalation of 400 μg of albuterol. The main goal of this prospective observational study was to perform a multidimensional evaluation of the evolution of COPD patients to better define the natural history and phenotypes of the disease (ClinicalTrials.gov Identifier: NCT01122758).
The recruitment period was from 15 January 2010 to 31 March 2012. The participated patients are currently being followed up, but the available data at the time of analysis (February 2016) for the present study were collected from the baseline and the 2-year appointments. We evaluated anthropometric data, that is, age, gender, height, weight and body mass index (BMI), pack-year history, respiratory symptoms (modified Medical Research Council (MMRC) dyspnoea scale), healthrelated quality of life using the COPD Assessment Test (CAT), respiratory function (post-bronchodilation FEV 1 and FVC % of predicted) and exercise tolerance by the 6-min walking distance (6MWD) test. A detailed questionnaire about the presence of co-morbidities was also administered to all patients. The presence of the following co-morbidities was registered: obstructive sleep apnoea (OSA), bronchiectasis, diabetes mellitus, hypertension (HTA), dyslipidaemia, metabolic syndrome, ischaemic cardiomyopathy, heart failure, atrial fibrillation, renal failure, peptic ulcer disease, anxiety, depression, cancer and osteoporosis. Patients with past history of asthma and asthma-COPD overlap syndrome (ACOS) were included in the analysis.
Patient data were anonymized in a database with hierarchical access control in order to guarantee secure access to the information. To be included in the study, the participants provided informed consent as it was approved by each of the ethics committees of the participating centres (Comité de Etica de la Investigación, 
Clinical and physiological measurements
During a personal interview, trained personnel obtained the following information at the time of recruitment and at subsequent follow-up appointments yearly: age, gender and BMI. Smoking status (current or former) and smoking history (age at initiation and discontinuation, as well as intensity) were registered. From this information, we calculated the total smoking exposure and expressed it as pack-years. Pulmonary function tests were performed following the American Thoracic Society (ATS) guidelines and using the ATS reference values.
14 The 6MWD test was measured after selecting the best of two walks separated by at least 30 min. 15 Dyspnoea was evaluated by the MMRC scale (from 0 to 4). 16 To evaluate health-related quality of life, we used the CAT, a validated eight-item questionnaire, designed to assess and quantify the impact of COPD symptoms on patient health status. 17 We used the Spanish validated version of CAT, and it was selfadministered by each patient.
The ACOS was defined using some of the usual features stated by the Global Initiative for Asthma/Global Initiative for Chronic Obstructive Lung Disease (GINA/ GOLD) joint project stratified by major and minor criteria to increase the sensitivity and specificity to detect the overlap between COPD and asthma in this cohort as previously described. 18 
Statistical analysis
Quantitative data with a normal distribution were described using mean and SD. Quantitative data with non-normal distribution were described by median and interquartile range (IQR). Categorical data were described using relative frequencies. Paired sample ttest was used to compare normally distributed data and Wilcoxon signed-ranks test for non-normally distributed data.
K-means cluster method was used to classify patients into one of the three clinical phenotypic categories. The number of variables to include in the analysis was based on clinical criteria and availability of the data at baseline and 2 years. To represent the most important domains of the disease age, nutritional status, symptoms, exercise capacity and quality of life were included. The variables included were: age, pack-year history, BMI, FEV 1 %, FVC%, 6MWD, MMRC and CAT. The number of the categories was selected a priori, using results of the previous studies as guidance, [4] [5] [6] [7] [8] [9] which indicated that patients might fall into one of the three different clinical phenotypes: A, B and C. The stability of the clustering solutions was checked by repeating the procedure several times using different starting points, and checking the distance of cases from their cluster, to verify that there were no outliers. K-means cluster is an efficient procedure that attempts to identify relatively homogeneous groups of cases based on the selected characteristics. The algorithm requires the number of clusters in advance, so we selected three based on prior knowledge on the number of different phenotypes to be found. [4] [5] [6] [7] [8] [9] Ordering of the initial cluster centres may affect the solution if there are tied distances from cases to cluster centres. To assess the stability of a given solution, we have compared results from analyses with different permutations of the initial order of the cases. We used statistical package SPSS version 20.0 Inc. (Chicago, IL, USA). A P-value <0.05 was considered statistically significant.
RESULTS
A total of 521 smokers with COPD were evaluated at recruitment and at 2 years follow-up. Figure 1 shows the CONSORT diagram of the participants. Their clinical and physiological characteristics are provided in Table 1 . This large sample of mainly males, mostly former smokers with moderate degree of airway limitation patients, had a good exercise capacity, mild degree of dyspnoea and quality of life impairment. Their clinical characteristics remained mainly unchanged after 2 years of follow-up except for the CAT. Their treatment remained unchanged during the follow-up time. Table S1 and Figure S1 (Supplementary Information) show the baseline characteristics of patients who died or were lost during the follow-up time compared with those included in the final analysis. Statistically significant differences were only found in those lost in the follow-up in age, 6MWD, MMRC, prevalence of HTA, metabolic syndrome and atrial fibrillation. Table 2A shows the baseline characteristics of the three 'clusters' identified by the analysis and Table 2B shows the characteristics 2 years later. Cluster A is represented by younger COPD patients with better lung function, exercise tolerance and mild symptoms. Cluster C includes older patients with worse lung function, exercise tolerance and severe symptoms. Cluster B has COPD patients with clinical characteristics between the two previously described clinical clusters. Interestingly, patients assigned to this cluster have a higher prevalence of ACOS at baseline but the prevalence is the same in the three clusters after 2 years. Figure 2 shows the co-morbidities associated with the entire population and with each cluster. Patients included in cluster C have a higher prevalence of OSA, diabetes mellitus, HTA, dyslipidaemia, metabolic syndrome, atrial fibrillation, congestive heart failure and renal failure. Patients in cluster A have a lower percentage of co-morbidities. Figure 3 shows the percentage of patients who changed their cluster assignment during the 2 years followup time. An important percentage of patients changed their cluster assignment longitudinally: 20% of the patients at recruitment in A, 30% in B and 50% in C. Table S2 (Supplementary Information) shows in its different panels, the comparison between the parameters at recruitment and 2 years later of those patients Table 2 Clinical characteristics of the clusters identified at baseline and 2 years later Baseline clusters Clusters 2 years later who changed their cluster assignment. Regarding the patients in cluster A or B, exercise tolerance measured by the 6MWD was the main parameter driving these changes. Patients assigned to cluster C could only improve to B or A clusters and lung function, exercise capacity and quality of life were the main parameters responsible for their changes.
DISCUSSION
The main findings of this longitudinal analysis of clusters in stable COPD patients are: (i) patients were grouped into similar clusters at recruitment and 2 years later; (ii) an important percentage of patients (70% of them) remained in the same cluster at recruitment and 2 years later; and (iii) exercise tolerance, lung function and quality of life modifications were responsible for the changes in cluster assignment regarding the patients who changed after 2 years. The technique of 'cluster analysis' has been recently applied to COPD patients in an effort to organize heterogeneous variables into relatively homogenous groups. [4] [5] [6] [7] [8] [9] This could allow clinicians to identify different groups of patients with similar characteristics mainly for prognostic and therapeutic purposes.
Several studies have been published describing different COPD clusters, with variations in the type of clusters identified according to the population study and the variables included in the analysis: clinical, 4, 5 radiological, 8,9 biochemical 7,9 or genetic. 8 Two main clusters have been consistently found in most studies. One that included older patients with high BMI, highly symptomatic and with concomitant cardiovascular comorbidities as described by Burgel et al., 4, 5 Garcia Aymerich et al., 6 Vanfleteren et al. 7 and Rennard et al.
9
A second one that included patients with severe airflow limitation, disease exacerbations, nutritional depletion, muscle weakness and emphysema as described by Burgel et al., 4, 5 Vanfletteren et al. 7 and Rennard et al.
In the present study, patients included in cluster C could be represented by the first of the abovementioned cluster: older patients with lower FEV 1 %, high BMI, highly symptomatic and with concomitant co-morbidities such as diabetes mellitus, high blood pressure, metabolic syndrome, OSA and cardiovascular problems (atrial fibrillation, ischaemic cardiomyopathy and heart failure). Those in cluster A could be represented by the second cluster: younger patients with significant impairment of their lung function for their age, lower BMI and lower incidence of cardiovascular comorbidities. Interestingly Pinto et al. 19 performed a systematic review of previously published studies on cluster analysis in COPD patients, including eight studies in patients with similar characteristics (male from tertiary university hospitals, in this case with severe disease), reporting that the number of identified clusters goes from 2 to 5, although two were consistently identified similar to clusters C and A from our study.
Cluster B, the most prevalent, is an intermediate one that includes patients with clinical and physiological characteristics between the other two. This cluster could be similar to phenotypes 3 and 4 as described by Burgel et al. in their landmark studies of cluster analysis in COPD patients. 4, 5 The present finding is important, because it reproduces and most importantly validates previously described clusters, but in this occasion is a result of a multicentre, tertiary care level study with a large cohort of COPD patients.
The most relevant information provided by the present study is the longitudinal change pattern of clusters in a population of stable COPD patients. First, we proved that cluster analysis like the one performed in this study identified the same clusters at recruitment and 2 years later. Their characteristics did not change, which was an expected finding as it involves the same population. The selection of number of clusters was done a priori based on clinical judgement and previous reports, [4] [5] [6] [7] [8] [9] representing the different domains of the disease: age, symptoms, exercise capacity, quality of life and airway obstruction. The present study findings confirmed those from Esteban et al. 12 giving further longitudinal reproducibility to a technique that is becoming more popular for the identification of common clinical characteristics in COPD patients. 20 Second and most importantly, we also investigated the longitudinal variability of these clusters. We found that some patients assigned to one cluster at recruitment changed to a different cluster 2 years later (A: 20%, B: 30% and C: 50%). Although this information is not entirely novel, it is clinically relevant since it could imply that if a patient is identified as part of one cluster at a specific time, 2 years later he or she could belong to a different one even if the patient is under standard recommended therapy as it was the case with the patients included in this study.
Interestingly, the present study findings are similar to the ones from Esteban et al. 12 who also found that approximately 28% of their large population of stable COPD patients migrated to another cluster the year after, although there are differences in the study population and in the time of follow-up between the two studies. The present study population included patients from several Spanish centres, who were younger, had less degree of airway limitation and most importantly were followed up for a longer period of time.
The present study also confirms previous findings from Agusti et al., 21 who indicated that patients' classification (using the new GOLD classification) could change longitudinally in certain types of COPD patients (in their study those in groups B and C), although they did not use cluster analysis. Exploring this finding from another perspective, we could also say that those clusters with a more 'benign' clinical profile like clusters A and B are mainly stable after 2 years. However, half of the patients in cluster C, the ones with 'worse' clinical characteristics, progressed to a better clinical profile cluster after 2 years. This confirms previous findings from another COPD cohort, 22 indicating that in the longitudinal evolution of the disease, not all patients progress unfavourably, suggesting a more favourable prognosis and a better response to standard therapy. This could imply that regular standard therapy as the one applied to the patients included in the present work is effective in moving longitudinally patients into a more favourable cluster with likely a better prognosis, although that was not explored in the present work.
Third, we also explored the parameters associated with changes in cluster assignment and found that 6MWD, FEV 1 and CAT were the ones responsible for these changes and the magnitude of the change is well beyond the clinical significance of each parameter: 25 m for 6MWD, 4 points for CAT and 100 mL for FEV 1 . The fact that the clinical characteristics of COPD patients change longitudinally is not novel. Previous studies already reported that important parameters of the disease change longitudinally: 6MWD, dyspnoea MMRC and FEV 1 .
11 Esteban et al. 12 also reported that the parameters that changed after 1-year follow-up in their patients were exercise tolerance, certain lung function measurements and physical activity. This highlights the importance of longitudinal evaluation of clinical parameters in COPD patients, which mirrors better the natural history of the disease and the patients 'real life'. It also reinforces the importance of the longitudinal evaluation of exercise tolerance with the 6MWD, which provides relevant information about the longitudinal behaviour of the disease. 11 Again, these findings are relevant because they could have implications in the clinical management of these patients, as different studies have demonstrated that these parameters could be modified by therapeutic interventions such as bronchodilation 23 or pulmonary rehabilitation. 24 Interestingly and as described in previous works, patients in cluster C (older patients with lower FEV 1 %, high BMI and highly symptomatic) have a higher prevalence of co-morbidities such as diabetes mellitus, high blood pressure, metabolic syndrome, OSA, cardiovascular problems and interestingly a higher prevalence of ACOS. Clusters A and B have a similar prevalence of most of the described co-morbidities. Unfortunately, the small number of deaths (n = 16), does not allow to perform a solid statistical analysis to explore the potential role of the co-morbidities in each cluster mortality. Longer follow-up studies could answer this important question. There are several limitations in this study. First, we did not validate these clinical clusters against any important outcomes of the disease such as exacerbations or death. The number of exacerbations and deaths were small not allowing for a solid statistical analysis. The main purpose of the present study was to explore the longitudinal behaviour of clinical clusters in stable COPD patients. Second, the type of cluster analysis used (K means) has its own limitations: the number of clusters (K) is determined before the analysis and the algorithms locate the cluster centre and assign the subjects to the nearest cluster centre. This could limit the number of clusters and may accidentally exclude small but otherwise important group of subjects. 25 Also, K-means analysis does not allow the inclusion of categorical variables limiting the evaluation of potentially important ones such as the presence of co-morbidities that were not considered in this analysis. Third, the present multicentre study included only a small percentage of female patients, thus limiting the applicability of the findings mainly to male COPD patients. Larger samples of female COPD patients should be investigated to determine whether the longitudinal behaviour of clusters is the same between female and male COPD patients. Fourth, the present study only include changes that occurred during a 2-year period of follow-up that seems to be a short time frame for a disease with a long evolution time.
Lastly, the selection of patients only involves those who were alive and have complete data at baseline and 2 years, excluding from the analysis those patients who dropped out or died that tend to be more impaired, which could affect the construction of the baseline cluster locations. As shown in Table S1 and Figure S1 (Supplementary Information), the baseline characteristics, cluster assignment and co-morbidities of those patients that were lost in the follow-up differed from those included in the final analysis. This could have affected the final results of our analysis and therefore the main conclusion of the present work, although this is an event inherent to any longitudinal study.
In conclusion, the present longitudinal, multicentre study of stable COPD patients confirmed and validated previous findings that the same clusters could be identified at recruitment and 2 years later. It also confirmed that an important percentage of patients remained in the same cluster longitudinally and in those who changed are driven by important clinical modifiable parameters such as exercise tolerance, lung function and symptoms. Further longitudinal studies, especially with the inclusion of female patients, should be carried out to confirm these findings.
